Abstract:Objective: To study the relationship between zoledronic acid (ZOL) and vascular endothelial growth factor (VEGF) conformation so as to reveal the mechanism of bisphosphonates inhibiting angiogenesis. Methods: The binding structures of ZOL and VEGF were preprocessed and the molecular dockings were simulated through AutoDockTools, Discovery studio4 and AutoDockVina. The best binding conformation was accurately screened. The effects of various concentrations of ZOL (group A was 0 μmol/L, groups B, C and D were 25, 50 and 100 μmol/L, respectively) on human umbilical vein endothelial cell (HUVEC) proliferation, angiogenesis and angiogenic molecules were detected by using cell counting kit-8 (CCK-8) in vivo and in vitro angiogenesis, immunofluorescence and Western blotting. Results: There was a ZOL binding site on the target protein VEGF conformation. The affinity was -5.2 kcal/mol. This binding site consisted of the hydrophobic region composed of amino acids Cys26, 51, 57, etc. and the hydrogen bond binding region of the A chain (ASP34, SER50) and B chain (CYS61, 68, LEU66, GLY59). The results of CCK-8 showed that the levels of value A in groups B, C and D were significantly lower than that in group A at each time point from 3 to 6 days (P<0.05). In vitro vascular experiments demonstrated that the numbers of budding in groups B, C and D [(208±28), (151±21) and (62±9), respectively] were significantly lower than that in group A (276±30) (P<0.05). In vivo vascular experiments displayed that the ratio of Matrigel gel/plasma fluorescence in group A (0.003 1±0.000 3) was significantly higher than those in group B (0.002 1±0.000 2), group C (0.001 6±0.000 2) and group D (0.000 6±0.000 1) (P<0.05). The results of Western blotting revealed that the expression of VEGF in groups B, C and D [(0.72±0.11), (0.41±0.07) and (0.24±0.04), respectively] were significantly lower than that in group A (1.01±0.02) (P<0.05), and the expression levels of hypoxia-inducible factor-1α (HIF-1α) in groups B, C and D [(0.68±0.09), (0.55±0.06) and (0.43±0.08), respectively] were significantly lower than that in group A (0.96±0.04) (P<0.05). Conclusions: ZOL could inhibit cell proliferation, in vivo and in vitro vascularization and expression of VEGF/HIF-1α. The binding site of ZOL with the conformation of VEGF was located in the hydrophobic region and hydrogen-bonding region of amino acids. Designing an antagonist targeting this site might potentially alleviate the effect of ZOL in inhibiting angiogenesis.

Preparation and antitumor activity of zoledronic acid liposomes

In vitro and in vivo evaluation of cationic liposomes containing zoledronic acid as anticancer agent

Lipid bilayer-gated mesoporous silica nanocarriers for tumor-targeted delivery of zoledronic acid in vivo.

Codelivery of Zoledronic Acid and Double-Stranded RNA from Core-Shell Nanoparticles

Anti-breast cancer activity of resveratrol encapsulated in liposomes

Research Progress on Antitumor Effects of Zoledronic Acid

Augment the Efficacy of Eradicating Metastatic Lesions and Tumor Proliferation in Breast Cancer by Honokiol-Loaded Ph-Sensitive Targeted Lipid Nanoparticles

Hyaluronic acid-covered ferric ion-rich nanobullets with high zoledronic acid payload for breast tumor-targeted chemo/chemodynamic therapy

Polysialic Acid-Functionalized Liposomes for Efficient Honokiol Delivery to Inhibit Breast Cancer Growth and Metastasis.

[Molecular Mechanism of Zoledronic Acid Inhibiting Angiogenesis by Semi Flexible Binding with Vascular Endothelial Growth Factor Conformation].

Effect of Metronomic Use of Zoledronic Acid (ZOL) on Antitumor and Antiosteoclastic Effects in Breast Cancer Patients with Bone Metastasis

Hypoxia-Responsive Stereocomplex Polymeric Micelles with Improved Drug Loading Inhibit Breast Cancer Metastasis in an Orthotopic Murine Model.

Preparation of Liposome Gel by Calcium Cross-Linking Induces the Long-Term Release of DOX to Improve the Antitumor Effect

Zoledronic Acid Sensitizes Breast Cancer Cells to Fulvestrant Via ERK/HIF-1 Pathway Inhibition Inï¿½vivo

Dual-active targeting liposomes drug delivery system for bone metastatic breast cancer: Synthesis and biological evaluation

Dosing of zoledronic acid with its anti-tumor effects in breast cancer

Optimization of oxaliplatin long circulated liposomes by Taguchi orthogonal design

Replacing cholesterol with asiatic acid to prolong circulation and enhance anti-metastatic effects of non-PEGylated liposomes

Preparation, Characterization, and Anticancer Efficacy of Evodiamine-Loaded PLGA Nanoparticles

Improving the targeting and therapeutic efficacy of anastrazole for the control of breast cancer: In vitro and in vivo characterization

New Insights into the Actions of Bisphosphonate Zoledronic Acid in Breast Cancer Cells by Dual RhoA-dependent and -Independent Effects